Compare RCKY & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCKY | ALXO |
|---|---|---|
| Founded | 1932 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 240.8M |
| IPO Year | 1996 | 2020 |
| Metric | RCKY | ALXO |
|---|---|---|
| Price | $33.49 | $2.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $40.00 | $3.50 |
| AVG Volume (30 Days) | 68.7K | ★ 952.5K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ 94.74 | 26.36 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $270,408,000.00 | N/A |
| Revenue This Year | $8.12 | N/A |
| Revenue Next Year | $4.90 | N/A |
| P/E Ratio | $195.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.28 | $0.41 |
| 52 Week High | $48.70 | $2.66 |
| Indicator | RCKY | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 58.24 |
| Support Level | $31.86 | $1.99 |
| Resistance Level | $34.36 | $2.30 |
| Average True Range (ATR) | 2.01 | 0.17 |
| MACD | -0.57 | 0.04 |
| Stochastic Oscillator | 14.13 | 77.95 |
Rocky Brands Inc is a designer, manufacturer, and marketer of premium footwear and apparel under brands such as Muck, XTRATUF, Rocky, Durango, Georgia Boot, Lehigh, Ranger, and the licensed brand Michelin. The company operates through three segments, with the wholesale segment generating the majority of revenue through sales of footwear and accessories to sporting goods stores, outdoor specialty stores, online retailers, marine stores, independent retailers, mass merchants, retail uniform stores, and specialty safety shoe stores. The retail segment focuses on direct-to-consumer sales through e-commerce platforms and company-operated stores, while the contract manufacturing segment includes sales to the U.S. military, private label production, and sourcing arrangements for customers.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.